Kalevi Kurkijärvi
Directeur Général chez Fibrogen Europe Oy
Profil
Kalevi Kurkijärvi is currently the Chief Executive Officer & Director at Innomedica Oy since 2021.
He is also the Chairman & Chief Executive Officer at Biketex Ltd.
since 1993.
Additionally, he holds the position of President & Chief Executive Officer at Pharmacia Diagnostics Production Oy, and Chairman at Idea Development ID Oy.
Previously, he served as the Managing Director at FibroGen.
Europe Oy starting from 1997 and as the Executive Vice President at Wallac Oy since 1984.
Dr. Kurkijärvi has held various former positions including Chairman & Chief Executive Officer at Bio Fund Management Oy from 1997 to 2010, President & Chief Executive Officer at Phadia AB, Chairman at Biotie Therapies Oy, Chairman at Curium Finland Oy, Chairman at Stick Tech Oy, Chairman at Hormos Medical Oy, Chairman at Hytest Oy from 2001 to 2018, Chairman at Bio Orbit Oy, Director at Paratek Pharmaceuticals, Inc. from 2000 to 2011, Independent Director at FibroGen, Inc. from 1996 to 2021, Director at Juvantia Pharma Oy, Executive Director at Suomen Itsenäisyyden Juhlarahasto, Deputy Director at Takara Bio Europe AB, and Director at Ark Therapeutics Oy.
Dr. Kurkijärvi obtained his doctorate degree from the University of Turku in 1992.
Postes actifs de Kalevi Kurkijärvi
| Sociétés | Poste | Début |
|---|---|---|
Fibrogen Europe Oy
 Fibrogen Europe Oy BiotechnologyHealth Technology Fibrogen Europe Oy develops and markets recombinant human collagens and gelatins for research purposes. It serves companies in the pharmaceutical, vaccine, medical device, diagnostic, industrial, food, cosmetic, and nutraceutical businesses. The company was founded on May 22, 1996 and is located at Helsinki, Finland. | Directeur Général | 01/01/2019 |
Innomedica Oy
 Innomedica Oy Miscellaneous Commercial ServicesCommercial Services Innomedica is an international business consulting company serving the biotechnology and pharmaceutical industries. It provides a range of professional business development and project management services to its clients in both the public and private sectors. Innomedica's service portfolio includes Business Development, Licensing & Partnering, Japan Markets and Project Management. It is active on a global basis, though it specializes in the North European and Japanese markets. Its people are its main asset. Its success is based on leveraging the experience of professionals from different disciplines to deliver value to its clients. Its team portrays backgrounds from experienced business people to skilled lawyers and biomedical scientists. Innomedica was founded in 1997, and is a privately held company. Its client base covers both private and public sectors, both large and small. | Directeur Général | 01/01/2016 |
| Biketex Ltd. | Directeur Général | 01/10/1993 |
| Wallac Oy | Corporate Officer/Principal | 01/02/1984 |
Idea Development ID Oy
 Idea Development ID Oy Advertising/Marketing ServicesCommercial Services Idea Development ID Oy is an advertising agency based in Helsinki, Finland. The Finnish company operates as an advertising agency. | Président | - |
| Pharmacia Diagnostics Production Oy | Directeur Général | - |
Anciens postes connus de Kalevi Kurkijärvi
| Sociétés | Poste | Fin |
|---|---|---|
| FIBROGEN, INC. | Directeur/Membre du Conseil | 30/06/2021 |
Hytest Oy
 Hytest Oy BiotechnologyHealth Technology Hytest Oy manufactures biological products. It operates as producer of monoclonal antibodies and antigens for the diagnostic industry. The company was founded in 1994 and is headquartered in Turku, Finland. | Président | 01/09/2018 |
Paratek Pharmaceuticals, Inc. /Old/
 Paratek Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Paratek Pharmaceuticals, Inc. operates as a pharmaceutical company that focuses on the discovery, development, and commercialization of medicines. The firm’s lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. The company was founded by Stuart B. Levy and Walter A. Gilbert on July 3, 1996 and is headquartered in Boston, MA. | Directeur/Membre du Conseil | 01/11/2011 |
| ░░░ ░░░░ ░░░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░░░░ ░░░░░░░░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Formation de Kalevi Kurkijärvi
| University of Turku | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| FIBROGEN, INC. | Health Technology |
| Entreprise privées | 19 |
|---|---|
Paratek Pharmaceuticals, Inc. /Old/
Paratek Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Paratek Pharmaceuticals, Inc. operates as a pharmaceutical company that focuses on the discovery, development, and commercialization of medicines. The firm’s lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. The company was founded by Stuart B. Levy and Walter A. Gilbert on July 3, 1996 and is headquartered in Boston, MA. | Health Technology |
Biotie Therapies Oy
 Biotie Therapies Oy Pharmaceuticals: MajorHealth Technology Biotie Therapies Oy engages in the research, development, and commercialization of pharmaceutical products. The company was founded by Markku Tapani Jalkanen and Sirpa Tuulikki Jalkanen in June 1992 and is headquartered in Helsinki, Finland. | Health Technology |
Bio Fund Management Oy
 Bio Fund Management Oy Investment ManagersFinance BioFund Management Oy is a venture capital and private equity investment firm headquartered in Helsinki with an office in Turku and a subsidiary in Copenhagen. BioFund was founded in 1997 by Dr. Kalevi Kurkijärvi, Seppo Mäkinen and Dr. Timo Petäjä. BioFund's main investors are institutions in Finland such as insurance firms, pension funds, foundations, and the European Investment Fund. The firm manages venture capital funds. | Finance |
Curium Finland Oy
 Curium Finland Oy Miscellaneous Commercial ServicesCommercial Services MAP Medical Technologies Oy engages in the development and manufacture of radiopharmaceuticals and radiochemical products. It provides positron-emission tomography diagnostic agents and single-photon emission computed tomography products. The company was founded by Mika Nyyssönen and Jarmo Haukka on March 13, 1991 and is headquartered in Tikkakoski, Finland. | Commercial Services |
| Wallac Oy | |
Stick Tech Oy
 Stick Tech Oy Medical SpecialtiesHealth Technology Stick Tech Oy engages in the development, manufacture, and marketing of products for dental reinforcements. It offers everStickC&B, a glass fibre reinforcement for minimally invasive composite bridges. The company was founded in 1997 and is headquartered in Turku, Finland. | Health Technology |
Juvantia Pharma Oy
 Juvantia Pharma Oy Miscellaneous Commercial ServicesCommercial Services Juvantia Pharma Oy discovers and develops pharmaceuticals and drugs. The firm develops products for the treatment of Parkinson's disease, depression and schizophrenia, vasoconstrictive disorders, fibro proliferative vasculopathies and chronic pain.The company was founded by Risto Arvo Sakari Lammintausta in 1997 and is headquartered in Turku, Finland. | Commercial Services |
Fibrogen Europe Oy
Fibrogen Europe Oy BiotechnologyHealth Technology Fibrogen Europe Oy develops and markets recombinant human collagens and gelatins for research purposes. It serves companies in the pharmaceutical, vaccine, medical device, diagnostic, industrial, food, cosmetic, and nutraceutical businesses. The company was founded on May 22, 1996 and is located at Helsinki, Finland. | Health Technology |
Hormos Medical Oy
 Hormos Medical Oy Pharmaceuticals: MajorHealth Technology Hormos Medical Oy discovers and develops novel hormonal therapies. It provides research and development of products to treat endocrine disorders associated with aging. The company was founded by Risto Arvo Sakari Lammintausta and Lauri Kangas in 1997 and is headquartered in Turku, Finland. | Health Technology |
Innomedica Oy
Innomedica Oy Miscellaneous Commercial ServicesCommercial Services Innomedica is an international business consulting company serving the biotechnology and pharmaceutical industries. It provides a range of professional business development and project management services to its clients in both the public and private sectors. Innomedica's service portfolio includes Business Development, Licensing & Partnering, Japan Markets and Project Management. It is active on a global basis, though it specializes in the North European and Japanese markets. Its people are its main asset. Its success is based on leveraging the experience of professionals from different disciplines to deliver value to its clients. Its team portrays backgrounds from experienced business people to skilled lawyers and biomedical scientists. Innomedica was founded in 1997, and is a privately held company. Its client base covers both private and public sectors, both large and small. | Commercial Services |
Phadia AB
 Phadia AB Medical SpecialtiesHealth Technology Phadia AB develops, manufactures and markets blood test systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases. The company was founded in 2004 and is headquartered in Uppdala, Sweden. | Health Technology |
Suomen Itsenäisyyden Juhlarahasto
 Suomen Itsenäisyyden Juhlarahasto Investment ManagersFinance Suomen Itsenäisyyden Juhlarahasto is a Finnish innovation fund directly under the Finnish parliament. It primarily invests in foreign and national funds while making selected follow-up investments in Finnish start-ups and later-stage companies. It can consider investing in foreign companies if it is purposeful for the fund's goals. Its investment focus is in the well-being of the Finnish people, environment, and the economy. The size of its initial venture is up to EUR 2 million and its average investment period per company is from 4 to 10 years. | Finance |
Takara Bio Europe AB
 Takara Bio Europe AB Miscellaneous Commercial ServicesCommercial Services Takara Bio Europe AB is a provider of stem cell derived products and technologies which will drive unprecedented innovation in drug discovery and regenerative medicine today and in the future. The company was first in the world to bring to the market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as drug discovery tools. Cellartis is also the single commercial source of ethically derived hES cell lines and has developed cell lines for a range of uses. This hES cell technology platform offers a path to tools and regenerative medicine discoveries of the future. The company was founded in 2001 and is headquartered in Gothenburg, Sweden. | Commercial Services |
| Ark Therapeutics Oy | |
Hytest Oy
Hytest Oy BiotechnologyHealth Technology Hytest Oy manufactures biological products. It operates as producer of monoclonal antibodies and antigens for the diagnostic industry. The company was founded in 1994 and is headquartered in Turku, Finland. | Health Technology |
| Bio Orbit Oy | |
| Biketex Ltd. | |
Idea Development ID Oy
Idea Development ID Oy Advertising/Marketing ServicesCommercial Services Idea Development ID Oy is an advertising agency based in Helsinki, Finland. The Finnish company operates as an advertising agency. | Commercial Services |
| Pharmacia Diagnostics Production Oy |
